The S&P/ASX 200 index (ASX: XJO) is home to 200 of the largest listed companies on the Australian share market.
Among these 200 companies are some true blue chip stars that could form the foundations for a winning portfolio.
But which ASX 200 shares should you consider buying right now? Two that have recently been named as buys are listed below:
CSL Limited (ASX: CSL)
The first ASX 200 share that analysts rate as a buy is CSL.
It is one of the worldâs leading biotherapeutics companies with a collection of industry-leading therapies. This includes therapies such as Privigen, Hizentra, Idelvion, and Afstyla.
But CSL is never one to rest on its laurels. As well as not being afraid to make major acquisitions, such as Vifor Pharma last year, the company reinvests in the region of 12% of its sales back into research and development (R&D) activities each year. This ensures that it has an R&D pipeline containing some potentially lucrative and life-saving therapies and vaccines.
Combined with its new plasma collection technology, the future looks bright for this ASX 200 blue chip star.
As a result, it will come as no surprise to learn that a large number of brokers are recommending CSL shares as a buy. One of those is Citi, which has a buy rating and $350 price target.
ResMed Inc. (ASX: RMD)
Another ASX 200 share that could be a great addition to your portfolio is ResMed.
If youâre one of the estimated one in five people with a sleep disorder globally, you might be well aware of ResMed and its products. Though, that said, with the vast majority of sufferers still undiagnosed, perhaps you wonât be.
However, with education around sleep disorders and the health risks they pose improving each year, ResMed looks well-placed to continue its solid growth long into the future. Particularly given its industry-leading products, R&D investment, and wide distribution network.
Goldman Sachs is bullish on ResMed. It currently has a buy rating and $38.00 price target on its shares.
The post Build your portfolio around these ASX 200 blue chip shares: brokers appeared first on The Motley Fool Australia.
FREE Investing Guide for Beginners
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of April 3 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Top defensive ASX shares to buy in April 2023
- Top brokers name 3 ASX shares to buy next week
- My top 5 ASX shares to buy and hold forever in anticipation of the bull market
- Here are the top 10 ASX 200 shares today
- The broker community’s 3 best ASX 200 shares to buy for 2023
Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/9MlqmFQ
Leave a Reply